Literature DB >> 7551415

Immunity and immunopathology to respiratory syncytial virus. The mouse model.

P J Openshaw1.   

Abstract

Infection with respiratory syncytial virus (RSV) is a major unsolved challenge for vaccine development. RSV is worldwide in distribution and infects almost all children during the first 2 yr of life. The mouse model of RSV lung disease has been very successful in reproducing many aspects of the human disease. In particular, the role of antiviral T cells in both eliminating virus and causing enhanced disease has been shown dramatically. This immunopathologic paradox is now more clearly understood than for any other common human infection, largely due to insights gained from the mouse model. This review focuses on the unique ability of different RSV proteins to prime for specific functional subsets in the mouse, and the association between sensitization to the major surface glycoprotein G, the induction of T helper 2 cells, and the subsequent appearance of lung eosinophilia during RSV infection.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7551415     DOI: 10.1164/ajrccm/152.4_Pt_2.S59

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  45 in total

1.  Type 2 cytokines predominate in the human CD4(+) T-lymphocyte response to Epstein-Barr virus nuclear antigen 1.

Authors:  P Steigerwald-Mullen; M G Kurilla; T J Braciale
Journal:  J Virol       Date:  2000-08       Impact factor: 5.103

2.  HLA class I-restricted cytotoxic T-cell epitopes of the respiratory syncytial virus fusion protein.

Authors:  A H Brandenburg; L de Waal; H H Timmerman; P Hoogerhout; R L de Swart; A D Osterhaus
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

3.  Respiratory syncytial virus infection results in airway hyperresponsiveness and enhanced airway sensitization to allergen.

Authors:  J Schwarze; E Hamelmann; K L Bradley; K Takeda; E W Gelfand
Journal:  J Clin Invest       Date:  1997-07-01       Impact factor: 14.808

Review 4.  Pathogenesis of lower respiratory tract infections due to Chlamydia, Mycoplasma, Legionella and viruses.

Authors:  P Andersen
Journal:  Thorax       Date:  1998-04       Impact factor: 9.139

5.  Th17 cytokines are critical for respiratory syncytial virus-associated airway hyperreponsiveness through regulation by complement C3a and tachykinins.

Authors:  Monali M Bera; Bao Lu; Thomas R Martin; Shun Cui; Lawrence M Rhein; Craig Gerard; Norma P Gerard
Journal:  J Immunol       Date:  2011-09-14       Impact factor: 5.422

Review 6.  Problems and prospects of developing effective therapy for common cold viruses.

Authors:  S L Johnston
Journal:  Trends Microbiol       Date:  1997-02       Impact factor: 17.079

7.  Systemic eosinophil response induced by respiratory syncytial virus.

Authors:  C A Lindemans; J L L Kimpen; B Luijk; J Heidema; D Kanters; C K van der Ent; L Koenderman
Journal:  Clin Exp Immunol       Date:  2006-06       Impact factor: 4.330

8.  Respiratory syncytial virus infection and G and/or SH protein expression contribute to substance P, which mediates inflammation and enhanced pulmonary disease in BALB/c mice.

Authors:  R A Tripp; D Moore; J Winter; L J Anderson
Journal:  J Virol       Date:  2000-02       Impact factor: 5.103

9.  Involvement of toll-like receptor 4 in innate immunity to respiratory syncytial virus.

Authors:  L M Haynes; D D Moore; E A Kurt-Jones; R W Finberg; L J Anderson; R A Tripp
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

10.  RNA interference inhibits respiratory syncytial virus replication and disease pathogenesis without inhibiting priming of the memory immune response.

Authors:  Wenliang Zhang; Ralph A Tripp
Journal:  J Virol       Date:  2008-09-25       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.